Literature DB >> 27843945

β-Catenin Expression Negatively Correlates with WIF1 and Predicts Poor Clinical Outcomes in Patients with Cervical Cancer.

Jinxiao Liang1, Hui Zhou2, Yongpai Peng2, Xiaofei Xie2, Ruixin Li2, Yunyun Liu2, Qingsheng Xie1, Zhongqiu Lin2.   

Abstract

Aberrant activation of the canonical Wnt pathway plays a significant role in cervical cancer (CC). However, limited data show the correlation between the cancer clinicopathological characteristics and the key molecules such as β-catenin and Wnt inhibitory factor 1 (WIF1). In this study, β-catenin and WIF1 expression were analyzed by immunohistochemistry for 196 patients with CC, 39 with cervical intraepithelial neoplasia (CIN), and 41 with normal cervical epithelium (NCE). Significant overexpression of β-catenin was detected in CC (67.9%) when compared to CIN (43.6%) or NCE (34.1%), p < 0.01, while low WIF1 expression was detected in CC (24.0%) when compared to CIN (59.0%) or NCE (58.5%), p < 0.001. Negative correlation was shown between β-catenin and WIF1 expression (r = -0.637, p < 0.001). In addition, multivariate analysis revealed that both lymph node metastasis and β-catenin expression were the independent prognostic factors not only for disease-free survival (HR = 5.029, p < 0.001; HR = 2.588, p = 0.035, resp.), but also for overall survival (HR = 5.058, p < 0.001; HR = 2.873, p = 0.031, resp.). Our findings indicate that, besides lymph node metastasis, β-catenin expression may also be a poor prognostic factor for CC while WIF1 could be a potential drug target for treatment of advanced CC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27843945      PMCID: PMC5098059          DOI: 10.1155/2016/4923903

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Cervical cancer (CC) is the fourth most common cancer in women. According to existing data, there were 528,000 registered new cases and 266,000 deaths only in year 2012 [1]. Most patients with early CC have good prognosis. By contrast, patients with a later cancer stage or metastatic CC have poor survival rate because of less effective treatments available [2]. Therefore, additional studies on late cancer development and prognosis methods are necessary. Aberrant activation of the Wingless-type (Wnt)/β-catenin (canonical Wnt pathway) is a very common pathway in human CC [3]. Recent molecular testing has demonstrated that the CC biological behavior may arise as a multistep gene process. Specifically, infection with human papillomavirus (HPV) could be “the first hit” [4], while the dysregulation of canonical Wnt pathway may be required as “the second hit” in cervical oncogenesis [3, 5, 6]. However, the mechanism involving Wnt pathway in CC is still not well understood and requires additional studies. In the canonical Wnt pathway, the binding of Wnts to a heterodimeric receptor complex stabilizes the β-catenin expression and leads to the activation of β-catenin target genes inside the nucleus [7, 8]. Furthermore, Wnt inhibitory factor 1 (WIF1) is an upstream secreted Wnt antagonist, first identified as highly conserved gene in the human retina [9]. WIF1 main function is to bind the extracellular Wnt ligands [10], disturbing the Wnt interaction with the receptors [7] and consequently leading to β-catenin degradation, therefore inhibiting the canonical Wnt pathway. Currently, there are dozens of studies regarding the correlation with β-catenin and various types of cancer [7, 11]. In most of these cases, elevated levels of β-catenin have been strongly correlated with poor cancer prognosis. However, so far, there have been limited reports focusing on the association between β-catenin, WIF1, and the clinicopathological characteristics in CC. In the present study, we investigated the association between the canonical Wnt pathway (β-catenin as the hallmark [7]), WIF1, and clinicopathological features of 196 patients with CC and analyzed their prognostic value in CC.

2. Materials and Methods

2.1. Patients and Tissue Samples

Between December 2002 and October 2007, 196 patients from the Department of Gynecologic Oncology (Sun Yat-Sen Memorial Hospital, Canton, China), diagnosed with CC (stages IA–IIB) and submitted to curative surgical resection, were recruited for this study. Cases were restricted to those who did not receive any tumor related treatment before surgery. The clinicopathological characteristics were summarized in Table 3. Furthermore, an additional 39 cervical intraepithelial neoplasia (CIN) and 41 normal cervical epithelium (NCE) samples were obtained from women undergoing hysterectomy for noncancerous diagnosis. Histological diagnosis and tumor stage and grade were determined according to the World Health Organization (WHO) and the International Federation of Gynecology and Obstetrics (FIGO) staging systems [12, 13]. All specimens were anonymously coded in accordance with local ethical guidelines (as stipulated by the Declaration of Helsinki). All study protocols were approved by the University Ethics Committee.
Table 3

Association between the expression of WIF1 and β-catenin and clinicopathological parameters of CC (stages IA–IIB).

VariableCasesWIF1 β-Catenin
Number(%)NegativePositive p a NegativePositive p a
Histologic subtype
 Squamous cell carcinoma17287.813339NS58114NS
 Adenocarcinoma2412.2168519
FIGO stage
 IA168.2133NS610NS
 IB1, IIA110252.077253171
 IB2, IIA26432.746182539
 IIB147.1131113
Tumor grade
 G13519.2278NS629NS
 G2/G314780.81123541106
Parametrial invasion
 Negative18694.914145NS62124NS
 Positive105.18219
Surgical margin involved
 No18996.414346NS63126NS
 Yes73.66107
Lymph node metastasis
 Negative14272.410339NS5191NS
 Positive5427.64681242
Tumor size (cm)
 ≤411759.79027NS3681NS
 >47940.359202752
Cervical stromal invasion
 ≤ one second8643.95630 0.002 2759NS
 > one second11056.193173476
Lymphovascular invasion
 Negative9361.66429 0.035 3360 0.017
 Positive5838.44991048
Age (years)
 ≤35∗∗ 3517.9305NS926NS
 >3516182.11194254107

NS: not significant; HPF: high-power field. aThe p value was determined using the χ 2 test. Significant p values are shown with bold font. The number of patients is less than 196 because of missing data. Age (range: 23–66 y, median: 42 y).

2.2. Immunohistochemistry (IHC) and Samples Evaluation

According to the previously described method [14, 15], IHC analysis was performed using anti-β-catenin antibody (CST, #9562, Boston, MA, America) and anti-WIF1 antibody-N-terminal (Abcam, ab71204, Cambridge, MA, America). Human breast tissues were used as positive controls; negative controls were obtained by replacing the primary antibodies with phosphate buffered saline. The staining of β-catenin was evaluated according to Maruyama's method [16]. If more than 10% of cancer cells were positively stained for cytoplasm and/or nuclei, the cells were regarded as β-catenin-positive expression. By contrast, membrane staining was only classified as β-catenin-negative expression; for WIF1 protein expression, nuclear staining was considered to be negative [17]. Finally, if more than 10% of cancer cells were positively stained for WIF1 in cytoplasmic and/or on cell membranes, the positive IHC results were recorded.

2.3. Statistical Analysis

All the statistical analysis was conducted using SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). Associations between the clinicopathological characteristics and the pattern of WIF1 and β-catenin expression were examined using Pearson's χ 2 test. Survival rates were calculated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate survival analyses were performed using the Cox regression model for DFS and OS. A forward stepwise procedure was used to identify independent variables in the multivariate analysis. p < 0.05 indicated statistical significance.

3. Results

3.1. IHC of β-Catenin and WIF1 and Their Correlation with CC

As shown in Figure 1 and Table 1, obvious membranous staining of β-catenin and nuclear staining of WIF1 were observed in most cancer and noncancerous samples; however, both staining patterns were considered to be negatively expressed. No significant difference was observed between β-catenin-positive expression ratios (cytoplasmic/nuclear staining) in CIN (17/39, 43.6%) compared to NCE (14/41, 34.1%). In addition, positive β-catenin expression was found in (133/196, 67.9%) cervical cancer samples (both with p < 0.01). Furthermore, low expression of WIF1 was significant in CC samples compared with CIN and NCE (p < 0.001). Briefly, from 149 WIF1 negative CC samples, 126 (84.6%) were β-catenin-positive. On the other hand, from 47 WIF1 positive CC samples, 40 (85.1%) were β-catenin-negative (p < 0.001), Table 2. Statistically, β-catenin expression had negative correlation compared to WIF1 expression (r = −0.637; p < 0.001).
Figure 1

WIF1 and β-catenin staining images of human cervical tissues by IHC. ((a), (c)) Positive cytoplasmic staining of WIF1 was observed in both NCE and CIN. ((b), (d)) Positive membranous staining with no cytoplasmic/nuclear staining of β-catenin was observed in both NCE and CIN. (e) Positive nuclear staining without membranous/cytoplasmic staining of WIF1 was observed in CC. (f) Positive cytoplasmic staining of β-catenin was observed in CC. Magnification: ×200 (hematoxylin counterstained). Insets are magnified images from selected areas (small squares).

Table 1

Comparison of WIF1 and β-catenin expression in NCE, CIN, and CC.

VariableCases (number) β-CateninWIF1
NegativePositive p a NegativePositive p a
CC19663133 (67.9%)<0.01b 14947 (24.0%)<0.001c
CIN392217 (43.6%)1623 (59.0%)
NCE412714 (34.1%)1724 (58.5%)

aThe p value was determined using the χ 2 test. b p < 0.01 was found in the ratio of β-catenin positive expression when compared to CC and CIN or CC and NCE; c p < 0.001 was found in the ratio of WIF1 positive expression when compared to CC and CIN or CC and NCE; no significant differences were observed when comparing CIN and NCE.

Table 2

The relationship of WIF1 and β-catenin in CC.

VariableWIF1 p a Correlation coefficient
(−)(+)
β-Catenin
 (−)2340 <0.001 −0.637
 (+)1267

aThe p value was determined using the χ 2 test.

3.2. IHC of β-Catenin and WIF1 in Representative Cases with CC

Images of WIF1 and β-catenin staining for representative CC cases were shown in Figure 2, which indicated that, with the decreased expression of WIF1, clearly increased expression of β-catenin was observed. Specifically, the expression of β-catenin was usually absent in patients who had the most intense cytoplasmic WIF1 staining while the staining of β-catenin was intense in those who had no cytoplasmic expression of WIF1.
Figure 2

Comparison of WIF1 and β-catenin expression in CC. The relationship of WIF1 and β-catenin immunostaining for three representative cases: ((a), (b)) Case  102, indicating strong WIF1 cytoplasmic staining and negative β-catenin cytoplasmic/nuclear staining; ((c), (d)) Case  169, which shows moderate immunostaining for both WIF1 and β-catenin; ((e), (f)) Case  4, showing negative WIF1 cytoplasmic staining and strong β-catenin cytoplasmic staining. Magnification: ×200. Insets are magnified images from selected areas (small squares).

3.3. Special WIF1 Staining Pattern of CC Cells with Mitotic Figures

WIF1 was usually found to be moderate-to-strong nuclear staining but without cytoplasmic staining in this study. However, as shown in Figure 3, another pattern of WIF1 staining was observed in mitotic figures in some CC samples, which were characterized by blue-staining (hematoxylin stain) nuclei and brown-staining (anti-WIF1 stain) cytoplasm and were registered for the first time. The individual mitotic figures could present pleomorphic appearances, such as mirror-image cells (Figure 3(a)) and sunflower-like cells (Figure 3(b)).
Figure 3

Pleomorphic WIF1 staining appearances of CC cells with mitotic figures. The blue-stained (hematoxylin stain) nuclei and brown-stained (WIF1 stain) cytoplasm were characteristic. (a) CC cells in metaphase with small short rod-like nuclei and medium-sized cytoplasm were shown on the right while CC cells in telophase with mirror image were seen on the left. (b) CC cells in prophase with round nuclei and intermediate-sized cytoplasm (sunflower-like appearance) were shown. (c) CC cells in triploid mitotic figures with apparently lobulated nuclei and abundant brown-stained cytoplasm were shown. Magnification: ×400. Insets are magnified images from selected areas (small squares).

3.4. The Expression of WIF1 and β-Catenin and Their Association with the Clinicopathological Features of CC

As shown in Table 3, β-catenin-positive expression was associated with a higher rate of lymphovascular space invasion (p = 0.017). Furthermore, WIF1 positive staining was associated with less cervical stromal invasion (p = 0.002) and a lower rate of lymphovascular space invasion (p = 0.035).

3.5. The Clinicopathological Features and Their Prognostic Values

During the median follow-up of 70 months (range: 60–121 months), 46/196 (23.5%) patients underwent CC recurrence. Among those patients, 41 (88.1%) died from cancer progression and 5 patients with recurrent vaginal or lymph node CC survived after surgery and adjuvant concurrent chemoradiotherapy. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 76.5% and 79.1%, respectively. CC patients with positive β-catenin expression had poorer 5-year DFS (69.9% versus 90.5%, p = 0.002; Figure 4(a)) and 5-year OS (72.9% versus 92.1%, p = 0.003; Figure 4(c)) than patients with negative β-catenin expression. Patients with positive WIF1 expression had longer 5-year DFS (91.5% versus 71.8%, p = 0.007; Figure 4(b)) and OS (93.6% versus 74.5%, p = 0.007; Figure 4(d)) than those with negative WIF1 results.
Figure 4

Kaplan-Meier 5-year disease-free survival (DFS) and 5-year overall survival (OS) curves for patients with cervical cancer. ((a) and (c)) Patients with β-catenin-positive tumors tended to have poorer DFS and OS. ((b) and (d)) Patients with WIF1-positive expression had significantly better DFS and OS than those with negative results.

The univariate analysis showed that advanced FIGO stage, parametrial invasion, positive surgical margin, lymph node metastasis, larger tumor size (>4 cm), and β-catenin expression were correlated with poorer 5-year DFS rate. In addition, lymph node metastasis (p < 0.001; hazard ratio (HR) = 5.029; 95% CI: 2.623–9.645) and β-catenin expression (p = 0.035; HR = 2.588; 95% CI: 1.071–6.251) emerged as independent predictors of 5-year DFS in multivariate analysis, Table 4. For 5-year OS, FIGO stage, parametrial invasion, positive surgical margin, lymph node metastasis, larger tumor size, and β-catenin expression were included in the multivariate analysis. Lymph node metastasis (p < 0.001; HR = 5.058; 95% CI: 2.524–10.137) and β-catenin expression (p = 0.031; HR = 2.873; 95% CI: 1.102–7.492) emerged as independent predictors of 5-year OS, Table 4.
Table 4

Univariate and multivariate analysis of factors associated with DFS and OS for patients with CC.

Variable5-year DFSc 5-year OSc
UnivariateMultivariated UnivariateMultivariated
p a p a HRb 95% CI p a p a HRb 95% CI
FIGO stage
 IA<0.001 NS 0.002 NS
 IB1, IIA1
 IB2, IIA2
 IIB
Parametrial invasion
 Negative 0.002 NS 0.007 NS
 Positive
Surgical margin involved
 No 0.008 NS 0.036 NS
 Yes
Lymph node metastasis
 Negative<0.001 <0.001 5.0292.623–9.645<0.001 <0.001 5.0582.524–10.137
 Positive
Tumor size (cm)
 ≤4<0.001 NS 0.001 NS
 >4
β-Catenin
 Negative 0.001 0.035 2.5881.071–6.251 0.002 0.031 2.8731.102–7.492
 Positive

DFS: disease-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; NS: not significant; HPF: high-power field. aSignificant p values are shown in bold font. bHR > 1 indicates that risk for recurrence/death increased; HR < 1 indicates that risk for recurrence/death decreased. cUnivariate and multivariate analyses and Cox proportional hazards regression model. dVariables associated with survival by univariate analysis were adopted as covariates in multivariate analyses.

4. Discussion

Dysregulation of Wnt pathway is involved in different diseases, including cancer. β-Catenin, the key factor of canonical Wnt pathway, conducts Wnt signals to the nucleus and upregulates oncogenes during tumorigenesis [7, 8]. It has been demonstrated that the expression of β-catenin can be upregulated in various cancers, including CC [3, 5, 18]. Consistent with previous reports [19-21], β-catenin accumulation inside the cytoplasm was found to be significantly increased in CC when compared with CIN and NCE in this study. In addition, by Cox regression analysis, it was shown that β-catenin-positive expression was significantly correlated with poor prognosis in 5-year DFS and 5-year OS. In the present study, a negative correlation between cytoplasmic/nuclear β-catenin accumulation and cytoplasmic WIF1 immunostaining (positive expression) was found. In addition, decreased WIF1 expression in CC was consistent with some previous studies which were based on human tumor study, such as gastrointestinal tract, kidney, glioblastoma, osteosarcoma, lung, pituitary, bladder, and oral cavity [17, 22–28]. Therefore, we hypothesize that the canonical Wnt pathway was activated, whereas the Wnt antagonist WIF1 was inhibited, by the multistep gene process in CC. Our results have suggested that WIF1 expression was negative in 94.7% of CC samples with β-catenin-positive expression (Table 2), while the results in Figure 2 support the association between downregulation of WIF1 and upregulation of β-catenin expression in CC. This may indicate that inactivation of WIF1 and accumulation of stabilized β-catenin are a gradual process during tumorigenesis and progression of CC. Our study showed that the positive staining of WIF1 was significantly reduced in patients with >1/2 cervical stromal invasion and lymphovascular space invasion, while positive staining of β-catenin was associated with lymphovascular space invasion. Furthermore, though no statistical significance was registered, the expression of WIF1 was much lower in the patients with surgical margin involvement (14.3%) and lymph node metastasis (14.8%) than in those with no surgical margin involvement (24.3%) or no lymph node metastasis (27.5%; Table 3). These results stand in support of the idea that WIF1 downregulation is an early event [6] and can potentially inhibit the early progression stage of CC by antagonizing canonical Wnt pathway. Recurrence in many advanced cancers has been associated with chemoresistance. The related mechanisms include tumor angiogenesis, maintenance of resistant cancer stem cells, dysregulation of cell cycle, and defects in apoptosis, which are all at least partly regulated by the canonical Wnt pathway [29]. The expressions of components related to this pathway are frequently altered. Increased expression of Wnt ligands was reported in breast cancer [30] and dishevelled in cervical cancer [31], while decreased expression of dickkopf-1 was reported in pancreatic cancer [32], secreted frizzled-related protein 1 (SFRP1) in lung cancer [33], and WIF1 in cervical cancer [6]. The potential therapeutic targets related to these compounds in cancer have been investigated through successful preclinical studies [34]. Therefore, just as in some other carcinomas [22, 35–37], WIF1 is a potent drug target in CC treatment. Although the cytoplasmic WIF1 staining pattern was consistent with previous studies [6, 14, 15], the moderate-to-strong brown nuclear staining of WIF1 was common in our study. In some CC cases, mitotic figures were cytoplasm-positive and nuclei-negative staining (Figure 3), which made them easily identifiable compared to nonmitotic cancer cells. These results indicate that the changes of the localization of WIF1 expression may be related to the uncontrolled CC cell division. However, at present, the reason of opposite cytoplasmic/nuclear WIF1 staining patterns between mitotic figures and nonmitotic CC cells is unclear. Lack of study on the mechanisms and functions of the translocation of WIF1 between mitotic figures and nonmitotic CC cells is a limitation of our study. Further investigations for the reason are needed.

5. Conclusions

Our results have demonstrated the upregulation of β-catenin and downregulation of WIF1 in CC samples compared to CIN and NCE. Along with clinicopathological characteristics, such as lymph node metastasis and cervical stromal invasion, increased β-catenin expression has been shown to be a poor prognostic factor for CC, indicating the aberrant activation of canonical Wnt pathway. Moreover, the WIF1 staining pattern in mitotic figures (IHC, cytoplasm-positive and nucleus-negative) was opposite to most other CC cells in this study, and the reason needs to be explored in the future.
  35 in total

1.  Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer.

Authors:  K Maruyama; A Ochiai; S Akimoto; S Nakamura; S Baba; Y Moriya; S Hirohashi
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

2.  Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.

Authors:  I Ramachandran; E Thavathiru; S Ramalingam; G Natarajan; W K Mills; D M Benbrook; R Zuna; S Lightfoot; A Reis; S Anant; L Queimado
Journal:  Oncogene       Date:  2011-10-17       Impact factor: 9.867

3.  FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2014-02-22       Impact factor: 3.561

Review 4.  WNT signaling: an emerging mediator of cancer cell metabolism?

Authors:  Victoria Sherwood
Journal:  Mol Cell Biol       Date:  2014-10-27       Impact factor: 4.272

5.  Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.

Authors:  Shinji Urakami; Hiroaki Shiina; Hideki Enokida; Toshifumi Kawakami; Takashi Tokizane; Tatsuya Ogishima; Yuichiro Tanaka; Long-Cheng Li; Leopoldo A Ribeiro-Filho; Masaharu Terashima; Nobuyuki Kikuno; Hiroyuki Adachi; Tatsuaki Yoneda; Hirofumi Kishi; Kazushi Shigeno; Badrinath R Konety; Mikio Igawa; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

6.  WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix.

Authors:  Amber L Delmas; Bridget M Riggs; Carolina E Pardo; Lisa M Dyer; Russell P Darst; Eugene G Izumchenko; Mänette Monroe; Ardeshir Hakam; Michael P Kladde; Erin M Siegel; Kevin D Brown
Journal:  Carcinogenesis       Date:  2011-08-26       Impact factor: 4.944

7.  Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression.

Authors:  Aykut Uren; Shannon Fallen; Hang Yuan; Alp Usubütün; Türkan Küçükali; Richard Schlegel; Jeffrey A Toretsky
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

Review 8.  Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.

Authors:  Phuong N Le; Jessica D McDermott; Antonio Jimeno
Journal:  Pharmacol Ther       Date:  2014-08-27       Impact factor: 12.310

9.  Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Karl-Anton Kreuzer
Journal:  Eur J Cancer       Date:  2009-09-02       Impact factor: 9.162

10.  The negative regulators of Wnt pathway-DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival.

Authors:  Jarosław Paluszczak; Joanna Sarbak; Magdalena Kostrzewska-Poczekaj; Katarzyna Kiwerska; Małgorzata Jarmuż-Szymczak; Reidar Grenman; Daniela Mielcarek-Kuchta; Wanda Baer-Dubowska
Journal:  Tumour Biol       Date:  2014-12-07
View more
  7 in total

1.  Association of low expression of E-cadherin and β-catenin with the progression of early stage human squamous cervical cancer.

Authors:  Jing Jiang; Xinling Li; Xiangmei Yin; Jieying Zhang; Bin Shi
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

2.  Diagnostic value of WIF1 methylation for colorectal cancer: a meta-analysis.

Authors:  Haochang Hu; Bin Li; Cong Zhou; Xiuru Ying; Min Chen; Tianyi Huang; Yuehong Chen; Huihui Ji; Ranran Pan; Tiangong Wang; Danjie Jiang; Yanfei Chen; Yong Yang; Shiwei Duan
Journal:  Oncotarget       Date:  2018-01-03

3.  HOXA5 inhibits the proliferation and neoplasia of cervical cancer cells via downregulating the activity of the Wnt/β-catenin pathway and transactivating TP53.

Authors:  Hong-Mei Ma; Nan Cui; Peng-Sheng Zheng
Journal:  Cell Death Dis       Date:  2020-06-04       Impact factor: 8.469

4.  FEZF1 is an Independent Predictive Factor for Recurrence and Promotes Cell Proliferation and Migration in Cervical Cancer.

Authors:  Yang Lan; Xuewei Xiao; Yu Luo; Zhengchi He; Xu Song
Journal:  J Cancer       Date:  2018-10-10       Impact factor: 4.207

5.  Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer.

Authors:  Yunyun Liu; Lingling Xie; Dongyan Wang; Da Li; Guocai Xu; Lijuan Wang; Hui Zhou; Yuefei Yu; Zhongqiu Lin; Huaiwu Lu
Journal:  Cancer Manag Res       Date:  2018-09-26       Impact factor: 3.989

6.  NHERF1 inhibits beta-catenin-mediated proliferation of cervical cancer cells through suppression of alpha-actinin-4 expression.

Authors:  Qiqi Wang; Qiong Qin; Ran Song; Chunjuan Zhao; Hua Liu; Ying Yang; Siyu Gu; Deshan Zhou; Junqi He
Journal:  Cell Death Dis       Date:  2018-06-04       Impact factor: 8.469

7.  Association of C8orf4 expression with its methylation status, aberrant β-catenin expression, and the development of cervical squamous cell carcinoma.

Authors:  Chong Lan; Da-Wei Huan; Xiao-Cui Nie; Ju-Min Niu; Jian-Hua Sun; Wen-Jing Huang; Zhi-Han Li; Hong-Tao Xu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.